Partial agonist, telmisartan, maintains PPARγ serine 112 phosphorylation, and does not affect osteoblast differentiation and bone mass

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Kolli, Vipula ^a,b   Stechschulte, Lance A ^a   Dowling, Abigail R ^a   Rahman, Sima ^a   Czernik, Piotr J ^a   Lecka Czernik, Beata ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYAMINO ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SERINE; SERINE 112; SERINE 273; SOMATOMEDIN BINDING PROTEIN 2; TELMISARTAN; TRANSCRIPTION FACTOR FOXC2; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN 1; WNT10B PROTEIN; ANTIHYPERTENSIVE AGENT; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; BONE MASS; CELL DIFFERENTIATION; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; DRUG MECHANISM; ENERGY EXPENDITURE; INSULIN SENSITIVITY; LIPID STORAGE; LIPOGENESIS; MALE; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN DEPHOSPHORYLATION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; AGONISTS; ANIMAL; BONE; BONE DEVELOPMENT; CELL LINE; CYTOLOGY; DRUG EFFECTS; METABOLISM; OSTEOBLAST; PHOSPHORYLATION;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; BONE AND BONES; CELL LINE; MICE; OSTEOBLASTS; OSTEOGENESIS; PHOSPHORYLATION; PPAR GAMMA; SIGNAL TRANSDUCTION;

EID: 84901484832     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0096323     Document Type: Article

References (56)

1. Tontonoz P, Spiegelman BM (2008) Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem 77: 289-312.
2. Lecka-Czernik B, Gubrij I, Moerman EA, Kajkenova O, Lipschitz DA, et al. (1999) Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPAR-gamma 2. J Cell Biochem 74: 357-371. (Pubitemid 29344887)
3. Akune T, Ohba S, Kamekura S, Yamaguchi M, Chung UI, et al. (2004) PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest 113: 846-855. (Pubitemid 38544143)
4. Shockley KR, Lazarenko OP, Czernik PJ, Rosen CJ, Churchill GA, et al. (2009) PPARc2 nuclear receptor controls multiple regulatory pathways of osteoblast differentiation from marrow mesenchymal stem cells. J Cell Biochem 106: 232-246.
5. Lazarenko OP, Rzonca SO, Hogue WR, Swain FL, Suva LJ, et al. (2007) Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology 148: 2669-2680. (Pubitemid 46984815)
6. Wan Y, Chong LW, Evans RM (2007) PPAR-gamma regulates osteoclastogenesis in mice. Nat Med 13: 1496-1503.
7. Lecka-Czernik B (2010) Bone Loss in Diabetes: Use of Anti-diabetic Thiazolidinediones and Secondary Osteoporosis. Current Osteoporosis Reports 8: 178-184.
8. Liu L, Aronson J, Huang S, Lu Y, Czernik P, et al. (2012) Rosiglitazone inhibits bone regeneration and causes significant accumulation of fat at sites of new bone formation. Calcif Tissue Int 91: 139-148.
9. Liu L, Aronson J, Lecka-Czernik B (2013) Rosiglitazone disrupts endosteal bone formation during distraction osteogenesis by local adipocytic infiltration. Bone 52: 247-252.
10. Ahmadian M, Suh JM, Hah N, Liddle C, Atkins AR, et al. (2013) PPARgamma signaling and metabolism: the good, the bad and the future. Nat Med 19: 557-566.
11. Choi JH, Banks AS, Kamenecka TM, Busby SA, Chalmers MJ, et al. (2011) Antidiabetic actions of a non-agonist PPARgamma ligand blocking Cdk5-mediated phosphorylation. Nature 477: 477-481.
12. Hu E, Kim JB, Sarraf P, Spiegelman BM (1996) Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma. Science 274: 2100-2103. (Pubitemid 27020707)
13. Hinds TD Jr, Stechschulte LA, Cash HA, Whisler D, Banerjee A, et al. (2011) Protein phosphatase 5 mediates lipid metabolism through reciprocal control of glucocorticoid and PPAR{gamma} receptors. J Biol Chem 286: 42911-42922.
14. Nedergaard J, Cannon B (2010) The changed metabolic world with human brown adipose tissue: therapeutic visions. Cell Metab 11: 268-272.
15. Wu J, Bostrom P, Sparks LM, Ye L, Choi JH, et al. (2012) Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human. Cell 150: 366-376.
16. Ohno H, Shinoda K, Spiegelman BM, Kajimura S (2012) PPARgamma agonists induce a white-to-brown fat conversion through stabilization of PRDM16 protein. Cell Metab 15: 395-404.
17. Asaba Y, Ito M, Fumoto T, Watanabe K, Fukuhara R, et al. (2009) Activation of renin-angiotensin system induces osteoporosis independently of hypertension. J Bone Miner Res 24: 241-250.
18. Shimizu H, Nakagami H, Osako MK, Hanayama R, Kunugiza Y, et al. (2008) Angiotensin II accelerates osteoporosis by activating osteoclasts. Faseb J 22: 2465-2475. (Pubitemid 351948664)
19. Gu SS, Zhang Y, Li XL, Wu SY, Diao TY, et al. (2012) Involvement of the skeletal Renin-Angiotensin system in age-related osteoporosis of ageing mice. Biosci Biotechnol Biochem 76: 1367-1371.
20. Lynn H, Kwok T, Wong SY, Woo J, Leung PC (2006) Angiotensin converting enzyme inhibitor use is associated with higher bone mineral density in elderly Chinese. Bone 38: 584-588.
21. Izu Y, Mizoguchi F, Kawamata A, Hayata T, Nakamoto T, et al. (2009) Angiotensin II type 2 receptor blockade increases bone mass. J Biol Chem 284: 4857-4864.
22. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, et al. (2004) Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 43: 993-1002. (Pubitemid 38579904)
23. Schupp M, Clemenz M, Gineste R, Witt H, Janke J, et al. (2005) Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. Diabetes 54: 3442-3452. (Pubitemid 43334334)
24. Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M, et al. (2003) Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 42: 76-81. (Pubitemid 36842239)
25. Usui I, Fujisaka S, Yamazaki K, Takano A, Murakami S, et al. (2007) Telmisartan reduced blood pressure and HOMA-IR with increasing plasma leptin level in hypertensive and type 2 diabetic patients. Diabetes Res Clin Pract 77: 210-214. (Pubitemid 46670421)
26. Mori H, Okada Y, Arao T, Nishida K, Tanaka Y (2012) Telmisartan at 80 mg/day increases high-molecular-weight adiponectin levels and improves insulin resistance in diabetic patients. Adv Ther 29: 635-644.
27. Henriksen EJ, Jacob S, Kinnick TR, Teachey MK, Krekler M (2001) Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension 38: 884-890. (Pubitemid 34258687)
28. Tagami T, Yamamoto H, Moriyama K, Sawai K, Usui T, et al. (2009) A selective peroxisome proliferator-activated receptor-gamma modulator, telmisartan, binds to the receptor in a different fashion from thiazolidinediones. Endocrinology 150: 862-870.
29. Ma L, Ji JL, Ji H, Yu X, Ding LJ, et al. (2010) Telmisartan alleviates rosiglitazone-induced bone loss in ovariectomized spontaneous hypertensive rats. Bone 47: 5-11.
30. Rahman S, Czernik PJ, Lu Y, Lecka-Czernik B (2012) beta-Catenin Directly Sequesters Adipocytic and Insulin Sensitizing Activities but Not Osteoblastic Activity of PPARgamma2 in Marrow Mesenchymal Stem Cells. PLoS One 7: e51746.
31. Lecka-Czernik B, Moerman EJ, Grant DF, Lehmann JM, Manolagas SC, et al. (2002) Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation. Endocrinology 143: 2376-2384. (Pubitemid 34521584)
32. Huang S, Kaw M, Harris MT, Ebraheim N, McInerney MF, et al. (2010) Decreased osteoclastogenesis and high bone mass in mice with impaired insulin clearance due to liver-specific inactivation to CEACAM1. Bone 46: 1138-1145.
33. Wolff GL, Roberts DW, Mountjoy KG (1999) Physiological consequences of ectopic agouti gene expression: the yellow obese mouse syndrome. Physiol Genomics 1: 151-163. (Pubitemid 129622462)
34. Bultman SJ, Michaud EJ, Woychik RP (1992) Molecular characterization of the mouse agouti locus. Cell 71: 1195-1204. (Pubitemid 23016553)
35. Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik B (2004) Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 145: 401-406. (Pubitemid 38094536)
36. Younis F, Stern N, Limor R, Oron Y, Zangen S, et al. (2010) Telmisartan ameliorates hyperglycemia and metabolic profile in nonobese Cohen-Rosenthal diabetic hypertensive rats via peroxisome proliferator activator receptor-gamma activation. Metabolism 59: 1200-1209.
37. Holdsworth DW, Thornton MM (2002) Micro-CT in small animal and specimen imaging. Trends in Biotechnology 20: S34-S39. (Pubitemid 34804433)
38. Lewis G, Nyman JS (2008) The use of nanoindentation for characterizing the properties of mineralized hard tissues: state-of-the art review. J Biomed Mater Res B Appl Biomater 87: 286-301.
39. Lazarenko OP, Rzonca SO, Suva LJ, Lecka-Czernik B (2006) Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat. Bone 38: 74-85.
40. Storka A, Vojtassakova E, Mueller M, Kapiotis S, Haider DG, et al. (2008) Angiotensin inhibition stimulates PPARgamma and the release of visfatin. Eur J Clin Invest 38: 820-826.
41. Araki K, Masaki T, Katsuragi I, Tanaka K, Kakuma T, et al. (2006) Telmisartan prevents obesity and increases the expression of uncoupling protein 1 in diet-induced obese mice. Hypertension 48: 51-57. (Pubitemid 44297524)
42. Shiota A, Shimabukuro M, Fukuda D, Soeki T, Sato H, et al. (2012) Activation of AMPK-Sirt1 pathway by telmisartan in white adipose tissue: A possible link to anti-metabolic effects. Eur J Pharmacol 692: 84-90.
43. Li YQ, Ji H, Shen Y, Ding LJ, Zhuang P, et al. (2009) Chronic treatment with angiotensin AT1 receptor antagonists reduced serum but not bone TGF-beta1 levels in ovariectomized rats. Can J Physiol Pharmacol 87: 51-55.
44. Cawthorn WP, Bree AJ, Yao Y, Du B, Hemati N, et al. (2012) Wnt6, Wnt10a and Wnt10b inhibit adipogenesis and stimulate osteoblastogenesis through a beta-catenin-dependent mechanism. Bone 50: 477-489.
45. Hedbacker K, Birsoy K, Wysocki RW, Asilmaz E, Ahima RS, et al. (2010) Antidiabetic effects of IGFBP2, a leptin-regulated gene. Cell Metab 11: 11-22.
46. Kawai M, Breggia AC, DeMambro VE, Shen X, Canalis E, et al. (2011) The heparin-binding domain of IGFBP-2 has insulin-like growth factor bindingindependent biologic activity in the growing skeleton. J Biol Chem 286: 14670-14680.
47. Tang Y, Wu X, Lei W, Pang L, Wan C, et al. (2009) TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med 15: 757-765.
48. Moerman EJ, Teng K, Lipschitz DA, Lecka-Czernik B (2004) Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR-gamma2 transcription factor and TGFbeta/BMP signaling pathways. Aging Cell 3: 379-389. (Pubitemid 40246708)
49. Grainger DJ, Percival J, Chiano M, Spector TD (1999) The role of serum TGFbeta isoforms as potential markers of osteoporosis. Osteoporos Int 9: 398-404. (Pubitemid 29231731)
50. Katavetin P, Eiam-Ong S, Suwanwalaikorn S (2006) Pioglitazone reduces urinary protein and urinary transforming growth factor-beta excretion in patients with type 2 diabetes and overt nephropathy. J Med Assoc Thai 89: 170-177. (Pubitemid 44743406)
51. Amano Y, Yamaguchi T, Ohno K, Niimi T, Orita M, et al. (2012) Structural basis for telmisartan-mediated partial activation of PPAR gamma. Hypertens Res 35: 715-719.
52. Qiang L, Wang L, Kon N, Zhao W, Lee S, et al. (2012) Brown Remodeling of White Adipose Tissue by SirT1-Dependent Deacetylation of Ppargamma. Cell 150: 620-632.
53. Seale P, Conroe HM, Estall J, Kajimura S, Frontini A, et al. (2011) Prdm16 determines the thermogenic program of subcutaneous white adipose tissue in mice. J Clin Invest 121: 96-105.
54. Rahman S, Lu Y, Czernik PJ, Rosen CJ, Enerback S, et al. (2013) Inducible brown adipose tissue, or beige fat, is anabolic for the skeleton. Endocrinology 154: 2687-2701.
55. Salisbury E, Hipp J, Olmsted-Davis EA, Davis AR, Heggeness MH, et al. (2012) Histologic identification of brown adipose and peripheral nerve involvement in human atherosclerotic vessels. Hum Pathol 43: 2213-2222.
56. Olmsted-Davis E, Gannon FH, Ozen M, Ittmann MM, Gugala Z, et al. (2007) Hypoxic adipocytes pattern early heterotopic bone formation. Am J Pathol 170: 620-632. (Pubitemid 47339399)